205 related articles for article (PubMed ID: 37097907)
1. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
[TBL] [Abstract][Full Text] [Related]
2. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
[TBL] [Abstract][Full Text] [Related]
3. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
[TBL] [Abstract][Full Text] [Related]
4. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
[TBL] [Abstract][Full Text] [Related]
6. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
7. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
Filler G; Tremblay O; Chen E; Huang SSH; Stein R
Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
[TBL] [Abstract][Full Text] [Related]
8. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
10. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
[TBL] [Abstract][Full Text] [Related]
11. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
[TBL] [Abstract][Full Text] [Related]
12. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study).
Smith PS; Gottesman GS; Zhang F; Cook F; Ramirez B; Wenkert D; Wollberg V; Huskey M; Mumm S; Whyte MP
J Bone Miner Res; 2020 May; 35(5):920-931. PubMed ID: 31910300
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?
Marcellino A; Bloise S; Pirone C; Brandino G; Gizzone P; Fraternali R; Dilillo A; Del Giudice E; Martucci V; Sanseviero M; Rita LM; Ventriglia F; Lubrano R
Monoclon Antib Immunodiagn Immunother; 2023 Jun; 42(3):104-108. PubMed ID: 37343168
[TBL] [Abstract][Full Text] [Related]
15. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study.
Mindler GT; Stauffer A; Kranzl A; Penzkofer S; Ganger R; Radler C; Haeusler G; Raimann A
Front Endocrinol (Lausanne); 2022; 13():866170. PubMed ID: 35399930
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
[TBL] [Abstract][Full Text] [Related]
17. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone.
Ertl DA; Le Lorier J; Gleiss A; Trabado S; Bensignor C; Audrain C; Zhukouskaya V; Coutant R; Berkenou J; Rothenbuhler A; Haeusler G; Linglart A
Orphanet J Rare Dis; 2022 Nov; 17(1):412. PubMed ID: 36371259
[TBL] [Abstract][Full Text] [Related]
18. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Burosumab in X-linked Hypophosphatemia.
Wang S; Wang X; He M; Li Y; Xiao M; Ma H
J Clin Endocrinol Metab; 2023 Dec; 109(1):293-302. PubMed ID: 37497620
[TBL] [Abstract][Full Text] [Related]
20. Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study.
Levy-Shraga Y; Levi S; Regev R; Gal S; Brener A; Lebenthal Y; Gillis D; Strich D; Zung A; Cleper R; Borovitz Y; Bello R; Tenenbaum A; Zadik Z; Davidovits M; Zeitlin L; Tiosano D
Eur J Pediatr; 2023 Nov; 182(11):5191-5202. PubMed ID: 37707589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]